PMID- 34485157
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined 
      With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical 
      Squamous Cell Carcinoma: A Randomized Controlled Trial.
PG  - 723193
LID - 10.3389/fonc.2021.723193 [doi]
LID - 723193
AB  - OBJECTIVE: To investigate the short-term efficacy and safety of Endostar combined 
      with concurrent chemoradiotherapy in the treatment of locally advanced cervical 
      squamous cell carcinoma (LACSC). METHODS: A total of 91 patients with LACSC 
      admitted to the First Affiliated Hospital of Anhui Medical University from June 
      2019 to December 2020 were randomly assigned to either the experimental group (n 
      = 48) or control group (n = 43). The control group received radiotherapy for 
      cervical cancer and paclitaxel combined with platinum chemotherapy (CCRT), and 
      the experimental group received Endostar continuous intravenous infusion of 
      anti-angiogenic therapy plus CCRT. The short-term efficacy, common clinical 
      indicators, tumor indicators, changes in serum vascular endothelial growth 
      factor-A (VEGF-A), and the occurrence of adverse events (AEs) were explored after 
      treatment. RESULTS: Compared with the control group, the complete response (CR) 
      rate in the experimental group was significantly increased (83.33% vs 65.12%, P < 
      0.05). Both routine indicators and tumor indicators in the two groups were 
      significantly decreased compared to before treatment. Compared with the control 
      group, patients in the experimental group had higher incidences of neutropenia, 
      hypertension, and infection, but lower incidence of nausea. After treatment, the 
      serological expression of VEGF-A was significantly decreased in both groups. 
      CONCLUSION: Endostar combined with CCRT in the treatment of LACSC can further 
      improve the efficacy of CR rate and significantly reduce serum tumor indicators 
      and VEGF-A levels, with mild and controllable AEs. Endostar combined with CCRT is 
      expected to be a new treatment regimen for LACSC.
CI  - Copyright (c) 2021 Shu, Dong, Xu, Luo, Xu, Zhu, Cheng and Lv.
FAU - Shu, Hang
AU  - Shu H
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Dong, Yaqin
AU  - Dong Y
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Xu, Zhonghua
AU  - Xu Z
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Luo, Weiwei
AU  - Luo W
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Xu, Lei
AU  - Xu L
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Zhu, Haochen
AU  - Zhu H
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Cheng, Linghui
AU  - Cheng L
AD  - Department of Obstetrics and Gynecology, First Affiliated Hospital, Anhui Medical 
      University, Hefei, China.
FAU - Lv, Yin
AU  - Lv Y
AD  - Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
LA  - eng
PT  - Journal Article
DEP - 20210813
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8414882
OTO - NOTNLM
OT  - concurrent chemoradiotherapy
OT  - endostar
OT  - locally advanced cervical cancer
OT  - safety
OT  - short-term efficacy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/07 06:01
PMCR- 2021/01/01
CRDT- 2021/09/06 06:06
PHST- 2021/06/10 00:00 [received]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/09/06 06:06 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/07 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.723193 [doi]
PST - epublish
SO  - Front Oncol. 2021 Aug 13;11:723193. doi: 10.3389/fonc.2021.723193. eCollection 
      2021.